Rare diseases and orphan drugs explained

What counts as a rare disease

In Europe and the UK, a disease is generally considered rare if it affects fewer than about 1 in 2,000 people. That sounds small, but there are more than 7,000 known rare diseases, and new ones are still being described. Because there are so many, around 1 in 17 people will be affected by a rare disease at some point in their lives — so collectively they are not rare at all. Most rare diseases are caused by changes in a single gene, and many appear in childhood, though some begin in adult life. They range enormously in how they affect people, from mild to life-limiting. Well-known examples include cystic fibrosis, muscular dystrophy, sickle cell disease and many inherited metabolic conditions, alongside thousands of conditions most people have never heard of.

The challenge of diagnosis

One of the hardest parts of living with a rare disease is simply getting a diagnosis. Because each condition affects so few people, many doctors may never have seen it, and symptoms can be mistaken for more common problems. Families often describe a long diagnostic journey, sometimes lasting years and involving many appointments and tests before an answer is found. Advances in genetic testing, including reading large parts of a person's DNA at once, are helping to shorten this journey and identify conditions earlier. Specialist centres and networks that focus on particular groups of rare diseases bring together expertise so that people can be assessed by clinicians who truly understand their condition. Getting the right diagnosis matters because it opens the door to appropriate care, monitoring, support and, where available, treatment.

What orphan drugs are

An orphan drug is a medicine developed specifically to treat a rare disease. The name reflects the fact that, in the past, these conditions were often 'orphaned' by drug development because so few patients meant companies had little incentive to invest. Developing any medicine is expensive, and doing so for a tiny number of patients can be hard to justify commercially. To change this, governments introduced special orphan drug rules that offer incentives — such as extra support during development, reduced fees and a period of market protection — to encourage companies to research treatments for rare diseases. These schemes have helped bring many new treatments to patients who previously had none. However, orphan medicines can be very expensive, which creates difficult decisions about funding within a health system with limited resources.

How treatments are funded in the UK

In the UK, decisions about which medicines the NHS provides are guided by careful assessment of how well a treatment works and whether it offers good value. For rare diseases, this is genuinely difficult, because studies are often small, long-term evidence may be limited, and prices can be high. Special processes exist to assess highly specialised treatments for very rare conditions, recognising that the usual rules may not fit. There are also arrangements that can allow access to promising treatments while more evidence is gathered, and schemes that help fund newer therapies. Patient groups play an important role in these discussions, bringing the real-world experience of living with a condition. Balancing hope for patients, fair use of NHS resources and the need for solid evidence is one of the most challenging areas in modern healthcare.

Living with a rare disease and finding support

Beyond medicines, people with rare diseases and their families need coordinated care and support. Because these conditions can affect many parts of the body, care often involves several specialists, and a named coordinator can help join things up. Specialist centres, sometimes far from home, provide expertise, and virtual clinics are increasingly used. Charities and patient groups are a lifeline, offering trusted information, peer support and a collective voice, and connecting people who may otherwise feel very alone. National plans, such as the UK Rare Diseases Framework, aim to speed up diagnosis, improve coordination and raise awareness among healthcare staff. Practical support with education, work, benefits and mental wellbeing matters too. Registering with specialist services and support organisations helps people stay informed about research and new treatment opportunities as they emerge.